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INTRODUCTION 
 
Uric Acid (UA) (C5H4N403) a prevalent of urine metabolism is 
predominantly used as a predictor of gouty diabetes. However as 
association of metabolic syndrome uric acid would worsen insulin 
resistance by disturbing insulin stimulator glucose uptake. Elevatedserum 
uric acid has been an independent risk factor for development of vascular 
complications in a diabetic patient. Hence is it essential for secondary and 
tertiary prevention. 
The kidney is an important regulator for circulating UA as is 
responsible for 60 to 70% of total body UA excretion. The remaining uric 
acid is secreted in to the intestine followed by the bacterial uricolysis. 
Diabetes mellitus is undoubtedly one the most challenging health 
problem in this century. Complications due to diabetes are a major cause 
of disability andreduce quality of life. The number of patientdiagnosed 
with complications each year is rising. Diabetic nephropathy is the 
leading cause of death for people with Type 2DM. 
Vascular complications of diabetes mellitus or classified in to 
microvascular and macro vascular complications.  
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Microvascular Complications: 
• Diabetic Nephropathy 
• Diabetic Neuropathy 
• Diabetic Retinopathy 
Macrovascular Complications: 
• Coronary Diseases 
• Cerebrovascular Diseases 
• Peripheral Vascular Diseases 
 Diabetes Mellitus 
• FBS greater or equal 126mg/dl 
• PPBS greater or equal 200mg/dl 
• HbA1c greater or equal 6.4 
• Diabetic Retinopathy - Fundus Examination 
• Diabetic Neuropathy - General Physical Examination, Neurological 
Examination 
• Diabetic Nephropathy - Microalbuminuria, Creatinine levels. 
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AIM 
 
 To assess the effect of Hyperuricemia as an added risk factor for 
microvascular complications in diabetic patients.  
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MATERIALS AND METHODS 
 
 
Types of Study: Hospital based observational study 
Place of Study: PSG Hospital, PSG IMS&R, Coimbatore 
Duration of Study: One year (April 2015- April2016) 
 
INCLUSION CRITERIA: 
• Diabetic patients diagnosed by ADA criteria 
• Age 20 to 80 years  
• Male and female  
 
EXCLUSION CRITERIA:DKA/HONK 
• GDM 
• Acute onset of disease 
• CKD 
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Methodology: 
 Obtained consent from all those who participated in this study. 
 This study was based on observational collection of data of 
diabetic patients with and without microvascular complications. 
 Patients underwent a history taking with general physical 
examination. (Age, sex, duration of disease) 
 Patients were scanned for diabetes by ADA criteria.  
 Patients were examined for vascular complications.  
 We divided them into 2 groups. 
I. Group I:Patients with diabetes without vascular complication 
II. Group II: Patients with diabetes and vascular complications. 
 Uric acid levels were observed for both the groups 
  Age, sex, duration of the disease was all most equal in both the 
groups. 
Result were computed to see if Hyperuricemia was an added risk 
factor for vascular complications in diabetic patients. 
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Patients are examined in detail and they are diagnosed diabetic based on 
ADA criteria. 
 
Diabetic complications were diagnosed by: 
Diabetic retinopathy: Fundus examination (ophthalmologist) , medical 
records, diagnosed by a medical practitioner. 
Diabetic neuropathy: nylon monofilament,general physical examination, 
medical record, diagnosed by a medical practitioner.  
Diabetic nephropathy: albuminuria, creatinine, medical records, 
diagnosed by a medical practitioner.   
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REVIEW OF LITERATURE 
History: 
Diabetes Mellitus was one of the earliest diseases portrayed (1) in 
an Egyptian Manuscript from around 1500 BC, the first described case 
being type 1 DM. (2) 
 
Around the same time, Indian physicians termed it “Honey urine”. 
The term diabetes was first used by the Greek God Apollonius of 
Memphis. The disease prevalence at that time was low probably due to 
the diet and life style followed by the people of that time. 
Effective treatment for diabetes was not developed until the early 
part of the 20
th
Century. Diabetesmellitus ,colloquially referred to 
asdiabetes is a multi-system metabolic disease in which there is high 
plasma sugar level(3). 
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Diabetes is caused by reduced amount of production of insulin by 
the pancreatic islets or due to peripheral receptor level resistance to 
insulindespite adequate circulating insulin levels (4). 
 Traditionally, Diabetes Mellitus has been classified as follows: 
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Type1DM: 
Type 1 DM results from an inadequate production of insulin from the 
beta cells of Islets of Langerhans. It was previously referred to as insulin 
dependent or juvenile diabetes but this term is redundant nowadays. The 
cause of this type is thought to be of auto-immune in etiology. 
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Type II DM: 
Primarily caused due to the receptor level resistance to insulin which 
arises due to a multitude of reasons, predominantly life-style related. As 
the disease progresses, this state of relative insulin deficiency becomes an 
absolute insulin deficient state. 
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Gestational Diabetes:  
The third main form occurs when pregnant women who previously 
did not have diabetes develop high blood sugar levels.  
 
As of 2015, an estimated 415 million people had diabetes (
6
). 
T2DM constitutes 90% of the cases (7, 8) and the prevalence among men 
and women were found to be comparable (9). The global economic cost 
of diabetes in 2014 was estimated to be USD 612 million
10
. 
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Other types of Diabetes Mellitus: 
Pre diabetes indicates a state in which a person’s blood glucose 
levels are higher than normal values but not high enough to qualify for a 
diagnosis of diabetes mellitus. 
LADA (Latent autoimmune diabetes of adults): Is a condition in which 
Type 1 DM – like picture develops in an adult. Adults with LADA are 
frequently misdiagnosed as having Type2 DM. 
Type III Diabetes: 
Is a term that is suggested for Alzheimer’s disease as the 
pathogenesis may involve insulin resistance in the brain
(15)
. 
The following is a comprehensive list of other causes of diabetes 
(16)
 
• Genetic defects 
• Genetic defects in insulin processing and action 
• Exocrine pancreatic defects 
• Environmental factors 
• Infections 
• Drugs 
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Signs and Symptoms: 
The classicalcluster of symptoms of untreated diabetes are  
• Weight loss 
• Polyuria 
• Polyphagia 
• Polydipsia
 (11)
.  
Symptoms may develop rapidly in type I DM, while they are slow to 
evolve in Type II DM. 
Several signs and symptoms can signal the onset of diabetes although 
they are not specific to the disease.They include  
• Blurred vision 
• Head ache 
• Fatigue 
• thirst 
• Slow healing of wounds 
• Itchy skin. 
• Hunger  
• Vaginal Infections 
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• Sudden weight loss 
• Tingling sensation of hands and legs 
• Frequent urination  
DIABETIC EMERGENCIES: 
Hypoglycemia: 
Low blood sugar (<60mg/dl) is considered to be hypoglycaemia. It 
is common in people with type I DM& type II DM on treatment. Effects 
can range from an uneasy feeling,sweating, trembling, increased appetite, 
change in behaviour to unconsciousness, coma and death. “Hypoglycemic 
unawareness” is a term that is applied to patients who do not experience 
any of the above-mentioned symptomsdespite profound hypoglycaemia, 
resulting from blunted autoimmune response in long-term diabetics. 
Diabetic Ketoacidosis: 
Patients with Type 1 DM might develop diabetic Ketoacidosis 
which is a metabolic disturbance characterised by nausea and 
vomiting,acidotic breathing, Kussmaul’s breathing, dehydration and 
decreased consciousness (12). It is characterised by blood sugar levels of 
more than 400mg/dl. A condition called Hyper-osmolar non-ketotic coma 
(HONK) is more common in Type 2 DM patients. 
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CHRONIC COMPLICATIONS OF DIABETES MELLITUS: 
The main chronic complications of Diabetes Mellitus include 
damage to the microvasculature. 
The next major set of complications of Diabetes Mellitus include 
damage to the larger vessels of the cardiovascular, cerebrovascular & 
peripheral vascular systems (13). 
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MICROVASCULAR COMPLICATIONS: 
Eye- Diabetic Retinopathy 
Diabetic Retinopathy is growth of friable neo-vasculature in the 
retina as well as macular oedema which can lead to severe vision loss. 
The presence of Diabetic Retinopathy is associated with visceral fat 
accumulation and insulin resistance in T2DM patients. An earlier study 
showed no significance difference in uric acid levels between patients 
with and without retinopathy (14).Retinal damage makes it the most 
common cause of blindness among non-elderly subjects. 
 
Blindness can be caused due to  
- Non resolving vitreous hemorrhage  
- Tractional  retinal detachment  
- Diabetic macular edema 
Patients may be asymptomatic in the early stages  
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Risk factors: 
• Duration of diabetes  
• Bad glycemic control 
• SHT 
• Nephropathy  
• Obesity 
• Smoking  
Classification:  
• Non proliferative diabetic retinopathy  
• Proliferative diabetic nephropathy 
• Clinical significant macular edema  
Non proliferative Retinopathy is further classified to: 
• Mild  
• Moderate 
• Severe  
• Very Severe  
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Non Proliferative diabetic retinopathy: 
Mild: 
• One micro aneurysm – earliest detectable lesion  
• Retinal hemorrhage  
Moderate:  
• Micro aneurysm + Hemorrhage in atleast one quadrant  
• Soft exudates  
• Venous bleeding or intra retinal microvascular abnormalities  
Severe: 
• Micro aneurysm + Hemorrhage in atleast four quadrant 
• Venous bleeding in two or more quadrant  
• Moderate IRMA in at least one quadrant  
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Very Severe: 
Any two features of 4-2-1 rule  
Proliferative retinopathy: 
Proliferation of new vessels, usually veins  
- New vessels on optic disk 
- New vessels elsewhere on retina  
Clinical significant macular edema: 
- Edema at the macula 
- Dimness of vision  
- Retinal edema close to fovea 
Causes:  
- Damage of blood vessels of retina  
- Microvascular leakage and occlusion  
- Micro aneurysm – out pouching of weakened capillary wall 
- Mild to moderate damage of blood vessels leaks fluid into retina 
(causes edema and exudates)  
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Microvascular occlusion 
 
Hypoxia of retina 
 
Re- establish circulation 
 
Vascular endothelial growth factor 
 
Neovascularization 
 
Bleeding 
 
Complications:  
- Vitreous hemorrhage  
- Retinal detachment  
- Glaucoma  
- Rubeosisiridis 
Management: 
Basic:  
• Control of disease  
• Associated factors  Lipids, renal failure, Systemic hypertension  
• Risk factors to be avoided (slows the progression of disease)  
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Mild and moderate: 
• No specific treatment  
• Control of diabetes  
• Fundus examination  
Severe and very severe: 
• Close follow up with ophthalmologist  
• Laser photo coagulation  
• Cataract surgery  
Clinically significant macular edema: 
1.  Focal or grid laser photo coagulation  
Laser (OP procedure) 
 
          Seals the leaking vessels from macula 
 
 Away from fovea  
2. Optical coherence tomography – non invasive  
3. Anti VEGF or intra vitreal injection of steroids  
 
Proliferative diabetic retinopathy: 
 Laser photo coagulation 
 Pan retinal photo coagulation  
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Surgical intervention: 
• Victrectomy (Remove exudates and clear hemorrhage) 
DIABETIC NEPHROPATHY: 
Damage to the kidney can lead to chronic renal failure eventually 
requiring dialysis. Diabetic mellitus is one of the most common causes of 
CKD. The typical pathological feature is Nodular Glomerulosclerosis, 
also called as Kimmelstein-Wilson disease. It also results in mesangial 
sclerosis. 
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Clinical syndrome: 
• Persistent albuminuria > 300mg / 24 hrs urine or > 200 mcg / min 
• Also called as macroalbuminuria 
• Microalbuminuria:  30 to 300 mg/dl/ 24 hrs 
Risk factors: 
- Familial  
- Polymorphism in angiotensin converting enzyme gene. 
- Male 
- Type II DM after the age of 50  
- Systemic hypertension  
- Obesity 
- Smoking  
Classification: 
Classified into 5 stages: 
- Stage of renal hypertrophy  and glomerular hyperfiltration 
- Stage of apparent normalcy  
- Stage of microalbuminuria 
- Stage of overt nephropathy 
- End stage renal disease  
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Stage I: 
Uncontrolled blood sugar 
 
Increased GFR, renal hypertrophy 
 
Insulin therapy 
 
Return to normal 
 
Stage II: 
Silent + glomerular hyperfiltration 
 
Blood sugar >250mg/dl 
 
Decreased GFR 
Stage III: 
• Important as it is reversible  
• 6 to 15 years after diabetes  
• Albumin 3 to 300 mg/dL /24 hrs 
• Increased blood pressure  
• Loss of dipping of nocturnal blood pressure  
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Stage IV: 
• Irreversible 
• 15 to 18 years of DM  
• GFR starts to decline at this rate (10ml/ min/year) 
• Microscopic hematuria  
• Nephrotic syndrome is seen  
 
Stage V: 
• 25 years of DM  
• GFR declines further more (20ml/ min/year) 
Pathogenesis:  
Hyperglycemia:Sorbitol pathway causes injury to the kidney  
Hypertension: Stress on the kidney that causes accumulation of protein in 
tubular cells that causes proteinuria. 
Screening:   
- Yearly screening of diabetics 
- Three times a year to check microalbuminuria (Preferably over 
night sample) 
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- Random urine albumin  to Creatinine ratio -collection in dipstick 
method  
When to look for differential diagnosis:  
 Absence of retinopathy  
 Sudden proteinuria without albuminuria  
 Macroscopic hematuria  
 Decline of GFR without proteinuria  
Management: 
Prevention is better  
- HbA1c<7% is best for reducing microalbuminuria 
Primary prevention:  
• From happening at all  
Secondary prevention:  
• Removing factors that progress kidney disease  
Tertiary prevention:  
• Proper management of CKD 
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Control of Hypertension: 
• Maintain BP at 130/85 – 125 / 75 in proteinuria patients  
• In the Absence of proteinuria maintain BP at (130/80)  
• Antihypertensives reduced mortality 
• ACE and ARB should be the drug of choice. 
Dietary Restriction:  
• Calories restriction  
• Proteins 0.8gms/ kg/ day  
• Potassium restriction 0.9gm/ kg/ day  
• Salt restriction  
• Avoid NSAIDS and aminoglycosides 
Monitor  
• GFR assessment monthly  
Supportive treatment: 
• Life style modification  
• Control of dyslipidimia 
• GFR <60ml 
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Treatment for Anemia:  
 Hemoglobin to be inbetween 11 to 12 gm/dl 
Erythropoietin in the dose of 50 to 150 units/kg/week is needed in CKD 
stage 4 and 5 
Renal replacement therapy:  
i. GFR <20ml/ min   
ii. Arterio-venous fistula  
iii.  Hepatitis B Vaccination 
iv. Hemodialysis  
v. Peritoneal dialysis 
vi. Transplantation  
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DIABETIC NEUROPATHY: 
Abnormal and decrease sensational: usually in a glove and stocking 
distribution starting with the feet but can also involve other nerves, later 
the fingers and hands. 
When combined with ischemic blood vessels can cause diabetic 
foot. Otherforms of neuropathy may present as mono neuritis. 
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Decline and damage of nerve function leading to loss of sensation  
 
 Ulceration  
 
 Amputation  
Neuropathy can be due to axon damage or demyelination.  
Axon damage may be due to subsequent regeneration of nerve fibers and 
may cause par aesthesis. 
Risk factors: 
- Poor glycemic control  
- Duration of disease  
- Damage of blood vessels  
- Mechanical injury to nerves  
- Genetic susceptibility  
- Alcohol  
- Smoking 
- Cardio vascular disease 
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Classification: 
- Sub clinical  neuropathy  
- Diffuse clinical neuropathy  
- Focal neuropathy  
 
 
Mono neuropathy  Entrapment syndromes  
 
Descriptive clinical classification: 
 
   Poly Neuropathy  
• Sensory  
• Motor  
• Acute sensory  
• Autonomic 
• Proximal motor  
• Truncal 
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Mono Neuropathy: 
• Cranial  
PATHOGENESIS 
Metabolic hypothesis:  
 
Persistent hyperglycemia + insulin deficiency  
 
Alters sorbitol pathway  
 
Increases advanced glycosylated end products  
 
  Increase oxidative stress 
 
  Nerve dysfunction 
 
Immune hypothesis: 
Auto antigens that induce immune response are anti phospholipids 
antibodies  
(Auto antibodies to gangliosides are seen to cause nerve dysfunction). 
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Microvascular hypothesis: 
Impaired vasoconstriction and vasodilatation   
 
Ischemia in nerves  
 
         Diabetic neuropathy 
Neurotrophic hypothesis: 
Neurotrophic factors like neurotrophin 3, neurotrophin 4/5,  
IGF I which are all necessary for survival of neurons are deficient in 
hyperglycemia hence causes nerve damage. 
Oxidative stress hypothesis: 
Free radical formation due to hyperglycemia causes endothelial cell 
dysfunction which leads to nerve damage. 
Small fiber neuropathy: 
Involves alpha and c fibers  
Sensory loss: 
- Pin prick hypoesthesia  
- Light touch sensation decrease  
- Monofilament increased  
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Symptoms: 
- Hyperalgisia (superficial pain +++)   
- Decreased sweating  
- Dryness of skin  
- Severe hyperesthesia  
- Hypoalgesia 
- Shock 
- Affected Areas:  Glove and stocking  
- No deformities 
- Motor deficit absent  
- Tendon refluxes or normal or decreased  
- Foot ulceration and gangrene 
Large fiber neuropathy: 
• Delta type A  
• Sensory loss is 0/ +++ 
• Decreased position sense  
• Decrease muscle strength  
• Reduced 2 point discrimination  
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Symptoms: 
- Deep seated pain  
- Dull aching pain 
- Ataxia  
- Fall  
- Trauma  
- Affected areas : lower limbs 
- Small muscle wasting on feet  
- Motor deficit +++ 
- Tendon reflex reduced 
- Foot ulcer high risk 
- Painful sensory neuropathy.  
  
  
39 
 
ASSESSMENT 
Nylon monofilament: 
• 2gms & 10gms (ADA) 
• 2g-purple 
• 10gms – red 
Quantitative sensory testing: 
• Vibration – tuning fork (128 HZ)  
Proximal motor Neuropathy: 
• Seen in Elderly  
• Gradual in onset  
• Pain followed by weakness 
• Begins as unilateral then becomes bilateral 
• Differential diagnosis:  Chronic inflammatory demyelination.  
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MANAGEMENT 
 
Small fiber Neuropathy:  
• Foot inspection 
• Sole mirror inspection 
• MCR foot wear 
• Well fit shoes  
• No heat exposure  
• Avoid fissures 
• Nail should be cut transversely   
Large fiber Neuropathy: 
• Gait and strength training  
• MCR  
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Medical management of DSPN: 
Control of:  
• Hyperglycemia  
• BP 
• Lipids  
• Life style 
Management of symptoms: 
Paresthesia and dysaesthesia 
• Tricyclic antidepressants (Amitriptyline)Contra indicated in 
CVDprostatic hyper trophy, glaucoma  
• Anti-convulsants 
• Carbamazepine 200-800mg / day  
• Gabapentin 300-1800mg / day  
• Pregabalin 150-600mg / day  
 
Deep seated pain: 
• Opioid derivatives ( Tramadol)  
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Focal Neuropathy: 
Mono neuropathy 
- Seen in older patients  
- Acute pain involves 3 and 6 cranial nerves  
- Self limiting in 6-8 weeks  
Treatment: 
• Symptomatic and  physiotherapy  
INSULIN 
Is a principal hormone that helps in uptake of glucose from the 
blood into most cells of the body especially liver, muscle and adipose 
tissue. Hence insulin deficiency place a critical role in all forms of DM 
[17].  
The body obtains glucose from four main places: 
• The intestinal absorption of food  
• The breakdown of glycogen,  
• The storage form of glucose found in tissue  
• Gluconeogenisis [18]. 
Insulin inhibits the process of the gluconeogenesis.  
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Insulin is released in to blood by β cells found in the islets of 
Langerhans in pancreas in response to raising levels of blood glucose. If 
the amount of insulin available is insufficient, cells respond poorly to 
effect of insulin or if the insulin itself is defective then glucose will not be 
absorbed properly by the body cells.[19] 
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When the glucose concentration in the blood remains high 
overtime the renal thresholdof reabsorption will be reached and glucose 
will be excreted [20]. 
This increasesosmotic pressure of urine and inhibits reabsorption 
of water by the kidney resulting in increased urine production and 
increasedfluids loss. 
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DIAGNOSIS 
 
DM is characterised by the recurrent or persistent high blood sugar 
and is diagnosed by any of the following [21] 
• Fasting Plasma glucose level ≥ 126mg /dl 
• Plasma glucose ≥ 200 mg / dl 2hrs after a 75 g oral glucose load. 
• Symptoms of High Blood sugar and RBS of ≥ 200mg /dl 
• HBA1C ≥ 6.5% [22] 
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Positive result should be confirmed by repeat of any of the above 
methods on a different day. It is preferable to measure a fasting glucose 
level because ofthe ease ofmeasurement.[23]According to current 
guidelines two fasting glucose measurements above 126mg/dl is 
considered for diagnosis for DM. 
According to WHO criteria people with FBS [110-125mg/dl] are 
considered to have impaired fasting glucose [24].People with plasma 
glucose at or above 140mg/dl but not over 200mg/dl: two hours after a 
75g diagnosed oral glucose load are diagnosed to have impaired glucose 
tolerance. 
ADA since 2003 uses a slightly different range forimpaired fasting 
glucose of [100 to 125mg/dl][25]. 
 
HbA1c is better than fasting glucose for determining risk of CVD 
and other death causes [26] 
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PREVENTION: 
There is noknown preventive measure for type1 diabetes [27] 
Type II diabetes which accounts for 85-90% of all cases can often 
be prevented or delayed byengaging in physical exercise and consuming a 
healthy diet. Higher level of physical activities reduces risk of diabetes by 
28% [28].Tobacco smoking is also associated with the increased risk of 
diabetes cessation can be taken as a preventive measure [29] 
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MANAGEMENT: 
Diabetes is a chronic illness for which there is no cure [30] 
Management mainly concentrates on maintaining close to normal 
blood sugar levels without causinghypoglycemia.Knowing about the 
diseases is very important in the treatment. Complications are less 
common in patient with good control [31 and 32] 
The goal in diabetes is aHbA1C ≥6.5.Other complications of 
diabetes should be monitored. Habits like smoking, increased cholesterol, 
fat, high BP should be controlled. Special foot wear available for patient 
with diabetes to reduce ulceration
33
. 
Life style modification playsa major role in diabetes patients. 
Central Obesity plays a major role in complications. Life style 
modification helps in reducing blood pressure
34
. 
Diabetic medications are available in different forms oral, 
injectable. Oral is Metformin, sulphonyl urea, GLP-1 agonist, 
thiazoledinediones SGLT2 inhibitors. Type2 DM is usually treated with 
Metformin and other drugs. There are studies that show it reduces 
mortality[35] Metformin works by reducing glucose production in the 
liver [36] 
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Oral drugs usually increase insulin release, reduce absorption of 
sugar from intestine and make the body more sensitive to insulin. While 
using injectable long acting is used first and then changed over to oral 
forms [37]Blood pressure monitoring is the most important in diabetic 
patient as cardio vascular disease is a serious complication. [38] 
 
It is harmful treating BP less than 140 mmHG [39]. Among drugs 
that reduce blood pressure angiotensionconverting enzyme inhibitors 
improve diabetic control. 
Surgical management can be considered in people with type1 
diabetes that is pancreas transplant [40].Inpatients with morbid obesity 
weight loss surgery can be done [41]. 
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HYPERURICEMIA 
Hyperuricemia has gained importance as many studies have 
reported that it not only has an important role in the development of 
metabolic disease but also microvascular risk factors 42-45.  Uric acid is 
primarily a purine metabolic waste product.About 70% of it gets excreted 
by the kidneys.  Hence decreased excretion of the uricacid is an important 
cause of hyperuricemia
46
.   
Few studies have reported that the prevalence of  hyperuricemia 
was associated with BMI and waist circumference 
47,48, 49
 associated with 
increasedleptin production and insulin resistance 
50, 51
 and both inversely 
correlated with renal clearance of urate. 
Nan et al reported that serum uric acid level decreased with 
increase of glucose level in patients with diabetes. Both glycemic control 
and function of beta cell decrease with increased duration of diabetes.   
Hyperfilteration by glomeruli caused by hyperglycemic state increases 
the excretion of uricacid. This may partly explain the inverse relationship 
between serum uricacid and diabetes 
52
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Serum uric acid levels are determined by a balance between uricacid 
production and excretion.  There is no method for detecting the uric acid 
production in humans. Uric acid production is indirectly calculated 
through serum Uric acid level and urine excretion.  The rate limiting step 
of uric acid production is an enzymatic reaction of the xanthine 
dehydrogenase/ xanthine oxidase enzyme that oxidises hypoxanthine – 
xanthine into uric acid.  It is absorbed in the liver and small intestine and 
it is the major source of uric acid 
53
. The enzyme is also produced in 
adipose tissue, vascular endothelium and macrophages all of which are 
involved in life style related diseases 
54.
 
The kidney is an important regulator of circulating uric acid and is 
responsible for 60-70 % of total body uric acid excretion 
55
.  The 
remaining uric acid is secreted into the intestine followed by bacterial 
uricolysis
55
.  Uric acid excretion includes uratesecretion and re-
absorption. An earlier study suggests the involvement of hyper 
filtration
56
.  During the secretion process, uric acid is transported into 
proximal tubular cells via OAT 1/3 and / or NADC3 and then secreted by 
HUA transporter sodium phosphate co transporter, ATP binding cassette.  
90% of uric acid filtered is reabsorbed 
55
.   
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Besides age, race, family, history of diabetes, glucose intolerance – 
serum uric acid has been suggested to be associated with complications of 
diabetes 
71
.  Elevated serum uric acid plays an important role in Type II 
DM and its complications.  Diabetogenic action of uric acid was reported 
in 1950 
(72).
  The mechanism of this is unknown.  Serum uric acid affects 
insulin resistence
73
. In summary a link between serum uric acid and 
insulin resistance has repeatedly been shown and uric acid itself plays an 
important role in exacerbation of insulin resistance 
74.
 
DIABETIC COMPLICATIONS AND URIC ACID LEVELS: 
Development of vascular complications were predicted 
independently by serum uric acid 
75
. We have discussed the relation 
between serum uric acid and each diabetic complication below.   
Diabetic Neuropathy: 
Diabetic neuropathy is a complication of the disease
76
.  It causes 
chronic numbness, loss of quality of life and pain.  The prevalence of 
diabetic neuropathy is associated with a significant increase of uric acid 
levels 
77.
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Several studies show that when controlled for factors such as age, 
gender, BMI and renal function, serum uric acid was high in patients with 
diabetic neuropathy 
78 -80
.   
The pathophysiology of diabetic neuropathy is not completely 
understood, there are multiple metabolic imbalance underlying in the 
development of diabetic neuropathy 
81.
 
Few risk factors for neuropathy are hyperglycemia, dyslipidemia 
and cardiovascular dysfunction. The polyol pathway, non-
enzymaticglycation, oxidative stress are believed to be causative factors.  
Oxidative stress and inflammation are involved in XDH/ XO activity.  
Therefore understood that uric acid generation by XDH/ XO play a role 
in diabetic neuropathy.   
Diabetic Retinopathy: 
Diabetic retinopathy is an accumulation of visceral fat and insulin 
resistance in diabetic patient 
82.
  Earlier reports stated no significant 
difference in uricacid levels in patients with or without diabetic 
retinopathy 
83
.   
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Recent studies show significant increase of uric acid level in 
diabetic retinopathy patients.  Serum uricacid is shown to be associated 
with severity of retinopathy.  COX – regression analysis showed that 
patients with serum uricacid levels in the third and fourth quartiles had 
increased serum uric acid levels compared to that in the first quartile 
84.
  
Vitreous uricacid and glucose concentration were higher in proliferative 
diabetic retinopathy than in NPDR.  Focal and uric acid production in 
vitreous is believed to be involved in pathogenesis and progression of 
diabetic retinopathy 
85.
 
Diabetic Nephropathy: 
Shichiri et al 
86
 proved that glomerular hyperfiltration occurs in 
non-insulin diabetes mellitus and that it lowers serum uricacid levels by 
increasing the renal clearance of urate
86.     
 
Other reports imply that high uricacid levels define the prognosis 
of diabetic nephropathy 
87
.   Serum uric acid is also associated with 
CKD
88.
 
Serum uricacid is associated with disease progression in early stage 
of nephropathy 
89.
  Serum uricacid concentration more than 6.3 mg/dl 
carries a poor prognosis in a diabetic patient with nephropathy.  Few data 
show association between uric acid and disease progression is 
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independent of diabetic control in a multivariate analysis. The 
progression and regression of urinary albumin excretion was not 
associated with uric acid levels 
90
.  Uric acid is an independent risk factor 
for renal dysfunction after adjustment for confounding factors.   
Uricacid is reduced in a diabetic patient due to hyperfiltration
91
.  
But reduced uricacid excretion during renal dysfunction increases serum 
uricacid levels.  There is data that suggest higher level of uric acid 
production is also involved in pathophysiology of neuropathy 
progression.   
Severalrecent studies are under way to delay nephropathy 
progression 
92 -94
.  Allopurinol significantly reduces serum uric-acid levels 
in hyperuricemic patients with diabetic complications.   
Diabetic foot: 
There are a few reports regarding the relationship between diabetic 
foot and uric acid levels.  One study states that elevated uric acid levels 
anindependent risk factor for diabetic foot in diabetic patient 
95
.    
 
 
 
  
57 
 
Significance of future uric acid metabolism research for the 
treatment of patients with diabetes:  
Xanthine dehydrogenase/xanthine oxidase has been studied for 
many years and allopurinol was used before enzyme inhibition therapy 
was found.  This progress in research is related to the global demand to 
target lifestyle related disease such as diabetes.  These researches have 
led to development of new powerful uric acid lowering agents.  
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FREQUENCY DISTRIBUTION OF SEX  
(MICRO COMPLICATION) 
 
S.NO AGE FREQUENCY PERCENTAGE 
1 MALE 24 48% 
2 FEMALE 26 52% 
 TOTAL 50 100 
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FREQUENCY DISTRIBUTION OF SEX  
(WITHOUT MICRO COMPLICATION) 
 
S.NO AGE FREQUENCY PERCENTAGE 
1 MALE 38 76% 
2 FEMALE 12 24% 
 TOTAL 50 100 
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FREQUENCY DISTRIBUTION OF AGE AND RETINOPATHY 
 
S.NO SEX RETINOPATHY TOTAL 
YES NO 
1 MALE 7 17 24 
2 FEMALE 12 14 26 
 TOTAL 19 31 50 
 
The Above table reveals that Retinopathy complication is more in female 
(12 patients) than in Male. 
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FREQUENCY DISTRIBUTION OF AGE AND NEUROPATHY 
 
S.NO SEX NEUROPATHY TOTAL 
YES NO 
1 MALE 5 19 24 
2 FEMALE 11 15 26 
 TOTAL 16 34 50 
 
The Above table reveals that Neuropathy complication is more in female 
(11 patients) than in Male. 
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FREQUENCY DISTRIBUTION OF AGE AND NEPHROPATHY 
 
S.NO SEX NEPHROPATHY TOTAL 
YES NO 
1 MALE 12 12 24 
2 FEMALE 7 19 26 
 TOTAL 19 31 50 
 
The Above table reveals that Nephropathy complication is more in male 
(12 patients) than in Female. 
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CHI-SQUARE TEST (HYPERURICEMIA AND RETINOPATHY) 
 
Null hypothesis: There is no association between Uric acid and 
Retinopathy 
 
H0: Uric acid and retinopathy are independent 
H1: Uric acid and retinopathy are not independent 
 Value Df Asymp. Sig (2 
sided) 
Pearson chi-square .683
a
 1 0.409 
Likelihood Ratio .675 1 .411 
N. of Valid cases 50   
 
Pearson chi-square value is .683with degree of freedom of 1. The 
significant value is 0.409(i.e. P value). Since P value is greater than 0.05, 
the difference between observed value and expected value is not 
significant. Therefore Null hypothesis is accepted. Thus there is no 
association between hyperuricemia and Retinopathy. 
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CHI-SQUARE TEST (HYPERURICEMIA AND NEPHROPATHY) 
Null hypothesis: There is no association between Uric acid and 
Nephropathy 
H0: Uric acid and Nephropathy are independent 
H1: Uric acid and Nephropathy are not independent 
 Value Df 
Asymp. Sig (2 
sided) 
Pearson chi-square 2.138
a
 1 0.144 
Likelihood Ratio 2.105 1 0.147 
N. of Valid cases 50   
 
Pearson chi-square value is 2.138 with degree of freedom of 1. The 
significant value is 0.144(i.e. P value). Since P value is greater than 0.05, 
the difference between observed value and expected value is not 
significant. Therefore Null hypothesis is accepted. Thus there is no 
association between hyperuricemia and Nephropathy. 
Inference: Uric acid is elevated in microvascular complication group 
when compared to no Complication group. Hyperuricemia is not 
independently associated with Nephropathy and Retinopathy and 
neuropathy.But uric acid is elevated in the microvascular 
complication group when taken as a whole. 
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DISCUSSION 
 
Diabetes Mellitus was one of the earliest diseases portrayed (1) in 
an Egyptian Manuscript from around 1500 BC, the first described case 
being type 1 DM. (2)Diabetes is caused either due to insufficient 
production of insulin by the pancreatic islets or due to peripheral receptor 
level resistance to insulin despite adequate circulating insulin levels (4). 
Increasing amounts of uric acid in the serum causes Gout and this 
is one of the most significant features oflifestyle-relateddisorder.Uric acid 
is primarily a purine metabolic waste protect about 70% of it gets 
excreted in the kidneys.  Hence decreased excretion of uric-acid is an 
important cause of hyper-uricemia
46
.  There is no method for detecting 
the uric acid production in humans. Uric acid production is indirectly 
estimated through serum Uric acid level and urine excretion. 
 Development of vascular complications were predicted 
independently by serum uric acid 
75
. 
 In a study conducted by Agrawal et al. it was concluded that the 
Uric acid levels are raised in patients with diabetes.They found lower 
levels of uric acid in diabetic subjects compared to healthy controls but 
higher level of uric acid in subjects of diabetes with retinopathy. This is 
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consistent with the finding of Navin S et al
107
 where they have suspected 
the pro-oxidant role of uric acid in causation of oxidative stress leading to 
diabetic complication like diabetic retinopathy, though they could not 
clearly state that the hyperuricemia in diabetic retinopathy is either a 
protective response (due to its antioxidant role) or a primary cause of it 
(due to its pro-oxidant role).
103
 In our study we found that out of the 50 
patients with micro-vascular complications 19 (38%) had retinopathy and 
out of this 7 patients (36.84%) had increased uric acid levels. This was 
also corroborated with a study conducted by Ching-Chao Liang et 
al.,where he concluded that there was increased serum uric acid levels 
which correlated with the severity of diabetic Retinopathy.
104 
In another study by JavadKiani et al., he showedthat there was 
increased level of serum uric acid in diabetic patientswith diabetic 
neuropathy.
105
How ever in our study we found that there was no 
significant correlation between uric acid levels and diabetic neuropathy. 
In a study conducted by YiliXu et al. he concluded that the patients 
with vascular complications had increased serum uric acid levels. He also 
said that this could be an independent predictor of vascular 
complications.
106
We found similar results in our study in which out of 50 
patients with vascular complications there were 15 patients (30 %) with 
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increased levels of uric acid as opposed to only 8 patients (16%) in 
patients without microvascular complications. 
Ito H. et al 
97
 demonstrated that HUA is associated with both 
microvascular and macrovascular complications of DM which was 
similar to the results of our study which showed that uric acid levels are 
raised in diabetic patients with microvascular complications. However, 
macrovascular complications were not assessed in our study.  
Nazir Shah et al.
98
 conducted a study in 2013 in 163 patients of 
diabetes mellitus (type 2) and proposed that elevation in the levels of uric 
acid was more in the diabetic patients with nephropathy (50%). In our 
study, it was found that 42% of patients with diabetic nephropathy had 
hyperuricemia which was similar to the study done by Nazir Shah et al. 
In a study conducted in 60 diabetic patients by Nasri et al. 
99
, it was 
proved that there was a significant association between diabetic 
nephropathy and the levels of uric acid in the patient’s serum which was 
in accordance with the results of our study. 
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PetterBjornstadet al
100
 stated that there is a relation between the 
uric acid level elevation and development of diabetic nephropathy which 
was also noted in our study. 
Su-Mi Kim et al.
101
 demonstrated that HUA contributes to the 
development of nephropathy in diabetic patients. In our study, we found 
that 8 out of 19 patients with diabetic nephropathy had elevated uric acid 
levels. 
In a study conducted by NS Nekiet al.
102
 in 400 diabetic patients, it 
was shown that there is a linear correlation between serum uric acid and 
development of nephropathy in patients with diabetes, which was also 
proved in the study done by us. 
 
Limitations of our study: 
• Small sample size 
• Macrovascular complications were not assessed  
• Contribution of drugs to Hyperuricemia not assessed. 
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CONCLUSION 
 
Hyperuricemia is one of the most sensitive indicators of 
microvascular complications caused due to Diabetes mellitus.
96
We 
conclude that there is a significant association of hyperuricemia and 
microvascular complications in patients with diabetes mellitus. Moreover, 
elevation in the uric acid levels was very strongly associated with 
nephropathy and retinopathy when compared to neuropathy. Therefore, 
early diagnosis and management of hyperuricemia is of utmost 
importance in the avoidance and management of diabetic complications. 
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ABBREVIATIONS 
DM Diabetes Mellitus 
UA Uric Acid 
SUA Serum Uric Acid 
HUA Hyperuricemia  
DR Diabetic Retinopathy 
DN Diabetic Nephropathy 
CKD Chronic kidney disease 
ADA American diabetes association 
WHO World health organization  
FBS Fasting blood sugar 
PPBS Post prandial blood sugar 
XDH Xanthine Dehydrogenase 
XO Xanthine Oxidase 
OAT Organic anion transporter 
NaDC3 N-acetyleaspartate dicarboxylate co-transporter 
BMI Body mass index 
NPDR Non proliferative diabetic retinopathy 
SUA Serum uric acid 
 
 
  
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
(strike off items that are not applicable) 
I DR Prashanth Arun, am carrying out a study on the topic:IsHyperuricemia a risk 
factor for vascular complications in patients with diabetes as part of our research 
project being carried out under the aegis of the Department of General Medicine. 
My research guide is: Dr.Sujayamenon 
The justification for this study is: To evaluate Hyperuricemia as an associated risk 
factor for vascular complications in patients with diabetes. 
The objectives of this study are: 
Primary Objective:To evaluate hyperuricemia as an associated risk factor for 
vascular complications in patients with diabetes. 
Sample size: 100 
Study volunteers / participants : 
1).Patients with diabetes 
2).Age >20<80years 
Location: PSG Hospitals 
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will be 
carrying out:  
  
Data collected will be stored for a period of 10 years. We will / will not use the 
data as part of another study. 
INITIAL INTERVIEW: Approximately 15 minutes 
Clinical examination will be done to asses other clinical findings…for example 
CNS examination to rule out Diabetic neuropathy. 
Methodology: .The study will be conducted in PSG Hospital 
Observational Study 
• Diagnosis of Diabetes by ADA criteria’s   
• Patients examined for vascular complications  
• Dividing them into 2 groups 
• .Patients with diabetes and patients with diabetes and vascular              
complications 
• Uric acid levels will be observed for both the groups. 
• .Age, sex, duration of the disease will be all most equal in both the groups. 
• .Result will be if Hyperuricemia is an added risk factor for vascular 
complications in a diabetic patient. 
Benefits from this study: To early diagnose risk factor for vascular complication 
in a diabetic patient. 
Risks involved by participating in this study:NIL 
How the results will be used:  
If you are uncomfortable in answering any of our questions during the course of 
the interview / biological sample collection, you have the right to withdraw from 
the interview / study at anytime. You have the freedom to withdraw from the 
study at any point of time. Kindly be assured that your refusal to participate or 
withdrawal at any stage, if you so decide, will not result in any form of 
  
compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a 
patient. You will NOT be paid any remuneration for the time you spend with us for 
this interview / study. The information provided by you will be kept in strict 
confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be 
used for approved research purposes only. You will be informed about any 
significant new findings - including adverse events, if any, – whether directly 
related to you or to other participants of this study, developed during the course 
of this research which may relate to your willingness to continue participation. 
Consent: The above information regarding the study, has been read by me/ read 
to me, and has been explained to me by the investigator/s. Having understood 
the same, I hereby give my consent to them to interview me. I am affixing my 
signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements).  
Signature / Left thumb impression of the Study Volunteer / Legal Representative:
  
Signature of the Interviewer with date:     Witness: 
 
Contact number of PI: 9940530630 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
  
  
 
  
  
 
  
  
 
  
  
MASTER CHART (PATIENTS WITH COMPLICATIONS) 
S. NO AGE/SEX D.RETINOPATHY D.NEPHROPATHY D.NEUROPATHY HBAIC FBS PPBS URIC ACID 
 55/M NO YES NO 8.7 105 152 10.2 
2 64/M NO YES NO 6.4 97 175 6.9 
3 38/F YES NO NO 6.3 148 158 8.4 
4 55/M YES NO NO 8.7 105 152 8.7 
5 53/F NO YES NO 6.2 98 189 6.9 
6 49/M YES NO NO 5.9 97 136 7.8 
7 49/M NO YES NO 5.9 97 136 7.8 
8 M/62 NO YES NO 10.2 100 193 8 
9 M/43 YES NO NO 6.5 133 186 7 
10 M/55 YES NO NO 14 95 162 2.5 
11 F/48 NO NO YES 7.6 125 194 5.3 
12 F/42 YES NO NO 10.2 125 200 4.2 
13 F/42 NO YES NO 10.2 125 200 4.2 
14 M/54 YES NO NO 9 127 135 3.8 
15 M/55 NO YES NO 7.2 100 183 5.3 
16 M/64 NO NO YES 10.1 130 147 5.3 
17 F/49 YES NO NO 6.6 102 131 9.2 
18 F/65 NO NO YES 5.8 100 158 4 
19 M/50 YES NO NO 7.2 74 130 5.4 
20 M/69 NO YES NO 6.9 300 387 9.2 
21 M/60 NO YES NO 9.6 107 200 4.2 
22 M/53 NO NO YES 8 189 208 6.4 
23 F/57 NO NO YES 11.1 95 194 2.5 
  
24 55/F YES NO NO 9.8 179 200 3.9 
25 55/F NO NO YES 14 209 326 3.9 
26 60/F YES NO NO 8.7 216 343 5.2 
27 50/F NO NO YES 7.1 126 259 3.9 
28 71/F YES YES YES 7.7 106 300 6 
29 71/F YES YES YES 7.7 106 300 6 
30 64/F YES NO NO 11.7 212 224 2.9 
31 66/F NO YES NO 6.46 126 201 9.2 
32 52/M NO YES NO 8.9 89 197 5.2 
33 50/F NO YES NO 8.2 143 179 3.7 
34 45/M NO YES NO 8.5 150 205 4.5 
35 60/M NO YES NO 8.9 110 197 5.2 
36 70/M NO NO YES 6.7 130 220 5.9 
37 60/F NO NO YES 8.23 120 179 3.7 
38 71/F NO NO YES 7.7 176 300 5.9 
39 61/M NO NO YES 6.4 178 224 4.4 
40 60/M NO NO YES 7.4 240 329 4.4 
41 70/F YES NO NO 7.7 176 300 5.9 
42 70/M YES NO NO 7.15 163 234 4.6 
43 70/F NO NO YES 13.2 152 201 4 
44 60/F YES NO NO 7.19 164 204 4.5 
45 F/49 YES NO NO 6.6 102 131 9.2 
46 50/M NO YES NO 8.7 158 254 10.2 
47 M/48 NO YES NO 8 180 250 9.2 
48 F/54 NO YES NO 6.46 125 200 9.2 
49 40/F YES NO NO 6.7 145 248 8.4 
50 F/42 NO NO YES 10.2 134 195 4.2 
  
MASTER CHART (PATIENTS WITHOUT COMPLICATIONS) 
S No. AGE COMPLICATION HBAIC FBS PPBS URIC ACID 
1 M/58 NO 10.2 207 227 4.2 
2 M/68 NO 7.7 123 252 4.9 
3 M/70 NO 9.17 101 230 1.7 
4 m/65 NO 8.9 126 157 5.1 
5 m/60 NO 7 110 183 5.4 
6 M/60 NO 6.3 97 162 5.8 
7 M/52 NO 7 127 142 8.1 
8 M/50 NO 5.4 96 120 2.9 
9 F/65 NO 6.4 127 154 1.4 
10 m/70 NO 7 90 131 2.8 
11 F/70 NO 6.6 80 200 5.4 
12 F/65 NO 5.7 87 112 5.5 
13 m/55 NO 6.3 132 150 5.5 
14 M/60 NO 6.1 85 153 6.8 
15 M/50 NO 8.9 190 220 2.1 
16 M/62 NO 8.9 72 120 3.3 
17 F/70 NO 6.1 82 172 4.1 
18 M/60 NO 6 115 132 2 
19 m/62 no 10.2 108 193 8 
20 m/69 no 6.8 76 152 1.8 
21 m/70 no 10.7 108 266 4.3 
22 m/45 no 6.5 119 155 6.6 
23 m/64 no 10.7 138 164 2.4 
24 m67 no 6.5 100 174 4.4 
25 m/42 no 5.1 114 136 7.8 
  
26 m/56 no 6.8 114 136 5 
27 m/64 no 7.5 96 200 9.4 
28 m/71 no 6.3 109 123 10.7 
29 m/52 no 7.2 159 234 6.3 
30 M/40 NO 8.8 190 250 5.3 
31 M/38 no 6.9 196 287 5.3 
32 60/m no 10.2 200 276 4.3 
33 68/m no 7.1 121 250 3.6 
34 50/m no 7.7 150 210 5 
35 75/m no 10.1 188 190 2.8 
36 77/m no 7.2 255 171 5.3 
37 68/m no 7 143 144 5.7 
38 46/m no 7.3 112 144 6.2 
39 80/m no 6.5 153 282 6.1 
40 57/m no 8.6 121 158 7 
41 55/f no 7.9 193 156 7.7 
42 54/f no 6.3 124 130 2.8 
43 60/f no 6.4 185 159 2.8 
44 73/f no 6.1 102 180 9.2 
45 38/f no 6.1 102 180 9.2 
46 m/70 no 8.6 119 138 5.1 
47 53/f no 7.5 146 196 4.2 
48 52/f no 8.12 293 345 3.8 
49 66/f no 10.2 161 237 4.2 
50 60/m no 10.2 103 198 4.2 
 
